Therapies

Astellas Bets On Gene Therapy With $3B Audentes Acquisition Offer

5 days ago   |   By Xconomy

Japanese drug giant Astellas Pharma announced late Monday it has agreed to buy Audentes Therapeutics, which is developing gene therapies for rare neuromuscular diseases. It's an all-cash deal worth $3 billion, with the Astellas offer of $60 per share representing a 110 percent premium to Audentes' share price of $28.61 apiece at market close Monday. The agreement is the latest big bet by a major pharmaceutical company on gene therapy, which aims to provide long-lasting, if not permanent, disease treatments. San Francisco-based Audentes' lead drug candidate, AT132, is a clinical-stage...
Read more ...

 

Astellas inks $3B Audentes buyout to expand in gene therapy

Astellas inks $3B Audentes buyout to expand in gene therapy

6 days ago   |   By Fierce Biotech

Astellas Pharma is set to buy Audentes Therapeutics for $3 billion. The deal will enable Astellas to set up a new genetic regulation unit spearheaded by a neuromuscular disease gene therapy that is set to be submitted for approval next year.
Read more ...

 


Search by Tags

   Therapies      Pharmaceutical      Pharma      Therapeutics      Drugs      Drug      Pharmaceuticals      Clinical      Gene      Genes      Gene Therapy      National      National blog main      National top stories      San Francisco blog main      San Francisco top stories      Acquisition      Antitrust      Astellas Pharma      Audentes      Big Pharma      Biotech      Buyout      Clinical trials      Deals      Drug Pricing      FDA      Joseph Schwartz      Life Sciences      M&A      Mergers      Neuromuscular disease      Orbimed      Rare disease      Regulatory review      Roche      Spark      Spark Therapeutics      Startup      SVB Leerink      Genetics  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

IAmScience Mannie Liscum

IAmScience Mannie Liscum

For Mannie Liscum, thinking is a privilege, and his job gives him the chance to be fascinated by human's capacity to conceptualize and learn new things. “It's my goal to use as... Read more ...

New Sanofi CEO Hudson adds next-gen cancer drug tech to the R&D quest...

When Paul Hudson lays out his R&D vision for Sanofi tomorrow, he will have a new slate of interleukin therapies and a synthetic biology platform to boast about. The French... Read more ...

AveXis Inc.: Senior Scientific Training Specialist - cGMP Gene Therapy

AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego... Read more ...

Process Engineer I - Genentech - Oceanside, CA

Focus will be on one or more areas such as design, implementation and/or start-up of new and/or existing facilities with respect to process and/or clean utility...From... Read more ...

Pineoblastoma segregates into molecular sub-groups with distinct...

Abstract Pineoblastomas are rare, aggressive pediatric brain tumors of the pineal gland with modest overall survival despite intensive therapy. We sought to define the clinical... Read more ...

The majority of A-to-I RNA editing is not required for mammalian homeostasis

Abstract Background Adenosine-to-inosine RNA editing, mediated by ADAR1 and ADAR2, occurs at tens of thousands to millions of sites across mammalian transcriptomes. A-to-I... Read more ...

CRISPR System: A High-throughput Toolbox for Research and Treatment of...

Abstract In recent years, the innovation of gene-editing tools such as the CRISPR/Cas9 system improves the translational gap of treatments mediated by gene therapy. The... Read more ...

Exploration of cryptic organic photosensitive compound as Zincphyrin IV in...

Abstract Zincphyrin IV is a potential organic photosensitizer which is of significant interest for applications in biomedicine, materials science, agriculture , and chemistry... Read more ...

Three transcriptional regulators positively regulate the biosynthesis of...

Abstract Polycyclic tetramate macrolactams are a widely distributed class of structurally complex natural products, and most of them exhibit multiple biological activities... Read more ...

Faint gray bands in Drosophila melanogaster polytene chromosomes are formed...

Abstract In Drosophila melanogaster , the chromatin of interphase polytene chromosomes appears as alternating decondensed interbands and dense black or thin gray bands... Read more ...